1-3 of 3
Markus Vähä-Koskela, PhD
Close
Sort by
Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2743.
https://doi.org/10.1182/blood-2018-99-116391
Published: 2018
Journal Articles

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

Mahesh Tambe, PhD, Ella Karjalainen, MSc, Markus Vaha-Koskela, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2210.
https://doi.org/10.1182/blood-2018-99-118289
Published: 2018
Journal Articles

Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model

Mette Matilda Ilander, MSc, Can Hekim, PhD, Markus Vähä-Koskela, PhD, Paula Savola, Siri Tähtinen, MSc, Leena Saikko, Akseli Hemminki, MDPhD, Panu Kovanen, MDPhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD
Journal: Blood
Blood (2014) 124 (21): 1408.
https://doi.org/10.1182/blood.V124.21.1408.1408
Published: 2014